Diurnal Group PLC
LSE:DNL
Intrinsic Value
Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of DNL.
Diurnal Group PLC's market capitalization is 46.3m GBX.
DNL stock price is 27.3 GBX.
DNL.
DNL. Open DCF Valuation
DNL. Open Relative Valuation
DNL has upside potential of 234% compared to the average analyst price target.
Open Wall St Estimates
DNL's Revenue has grown by 7% over the past 12 months.
DNL's ROE (Return on Equity) has significantly decreased in the last 3 years from -31% to -56%, and is approaching profitability.
DNL's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -137% to -325%, and is approaching profitability.
DNL has negative Operating Income for the last twelve months.
DNL has negative Net Income for the last twelve months.
DNL's ROE (Return on Equity) for the past 12 months is negative and is equal to -56%.
DNL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -325%.
DNL has positive Gross Profit for the last twelve months.
DNL has negative Free Cash Flow for the last twelve months.
DNL has negative three-year average ROE (Return on Equity): -55%. The company is not efficient at transforming stockholders' equity into net income.
DNL has negative three-year average ROIC (Return on Invested Capital): -279%. The company is not efficient at using invested capital to generate operating income.
DNL's short-term assets (26m GBP) exceed its short-term liabilties (5m GBP).
DNL's long-term assets (27m GBP) exceed its long-term liabilties (5m GBP).
DNL's D/E (Debt to Equity) is very low and is equal to 0.
DNL's Altman Z-Score is very low and is equal to -3.18.
Fundamental Analysis
Diurnal Group PLC
Balance Sheet Decomposition
Diurnal Group PLC
| Current Assets | 26.4m |
| Cash & Short-Term Investments | 16.5m |
| Receivables | 8.5m |
| Other Current Assets | 1.4m |
| Non-Current Assets | 200k |
| PP&E | 16k |
| Intangibles | 184k |
| Current Liabilities | 5m |
| Accounts Payable | 5m |
| Non-Current Liabilities | 32k |
| Other Non-Current Liabilities | 32k |
Earnings Waterfall
Diurnal Group PLC
|
Revenue
|
4.7m
GBP
|
|
Cost of Revenue
|
-1m
GBP
|
|
Gross Profit
|
3.7m
GBP
|
|
Operating Expenses
|
-22.5m
GBP
|
|
Operating Income
|
-18.8m
GBP
|
|
Other Expenses
|
2.3m
GBP
|
|
Net Income
|
-16.6m
GBP
|
Free Cash Flow Analysis
Diurnal Group PLC
DNL Profitability Score
Profitability Due Diligence
Diurnal Group PLC's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Diurnal Group PLC's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
DNL Solvency Score
Solvency Due Diligence
Diurnal Group PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Diurnal Group PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DNL Price Targets Summary
Diurnal Group PLC
According to Wall Street analysts, the average 1-year price target for
DNL
is 91.25 GBX
.
Shareholder Return
DNL Price
Diurnal Group PLC
| Average Annual Return | 53.32% |
| Standard Deviation of Annual Returns | 74.04% |
| Max Drawdown | -89% |
| Market Capitalization | 46.3m GBX |
| Shares Outstanding | 174 860 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Diurnal Group PLC
Country
Industry
Market Cap
Dividend Yield
Description
Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. The firm is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism. Its research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The firm's product, Alkindi, is a hydrocortisone specifically designed for use in children suffering from pediatric adrenal insufficiency (AI). Alkindi is an oral, immediate-release pediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children. Its pipeline includes Chronocort, DITEST, T3 modified release and Oligonucleotide (siRNA). Chronocort is a modified-release preparation of hydrocortisone that is specifically designed to mimic the circadian rhythm of cortisol.
You don't have any saved screeners yet
